Hello!
To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.
Brief
The Securities and Exchange Commission filed charges against three former biopharmaceutical company executives for scheming to conceal a harsh critique by the FDA about their cancer drug candidate, dovitinib. The SEC alleges that they misled investors with false claims about dovitinib's likelihood of approval while raising money to stay afloat. The SEC charges Carchedi, Foegh, and Cullem with violating securities laws, seeking permanent injunctions, disgorgement, civil penalties, and officer/director bars against the defendants. The investigation is being handled by the Boston Regional Office.
Highlights content goes here...
Hello!
To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
